SCHEMBL5287451

SCHEMBL5287451

O=S(=O)(c1ccc(Sc2cccc3ccccc23)c2nonc12)N1CCN(c2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
GAA P10253 2/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 5/20 0.46
POLB P06746 3/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
TP53 P04637 1/20 0.42
MCL1 Q07820 1/20 0.41
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALOX15 P16050 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5242720 0.88 ALDH1A1 (0.67) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL5244216 0.88 KMT2A (0.47) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL4746895 0.83 MAPT (0.49) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL5242905 0.82 KMT2A (0.49) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL5294598 0.82 ALDH1A1 (0.48) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL5292057 0.81 MEN1 (0.47) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL4745387 0.81 TSHR (0.51) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL4787536 0.80 ALDH1A1 (0.55) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL5291615 0.78 AVPR1A (0.39)
SCHEMBL5243664 0.77 ALDH1A1 (0.61) ALDH1A1GAAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP ALDH1A1 2627/4885GAA 488/4885MEN1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.